HONOLULU--(BUSINESS WIRE)--At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. (NASDAQ:ILMN) today announced its 2010 roadmap for the Infinium whole-genome genotyping platform, offering products capable of analyzing up to five million (5M) variants per sample. As part of this announcement, Illumina outlined an ongoing collaboration with leading researchers to select the highest-value markers from the 1000 Genomes Project for the next wave of genome-wide association studies (GWAS). This array content will facilitate testing new scientific hypotheses, including the impact of rare variants, CNVs, and other non-SNP markers on diseases and traits.
